Literature DB >> 7840348

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.

S Nyberg1, L Farde, C Halldin, M L Dahl, L Bertilsson.   

Abstract

OBJECTIVE: The aim of this study was to examine the relationships among clinical effects, central D2 dopamine receptor occupancy, and plasma concentrations of haloperidol in eight clinically stabilized schizophrenic outpatients who were responding to treatment with low doses of haloperidol decanoate.
METHOD: During a 4-week interval of haloperidol decanoate dosage (dose range = 30-50 mg), the patients' D2 receptor occupancy was determined with positron emission tomography on two occasions. Plasma concentrations of haloperidol were determined with a sensitive high-performance liquid chromatography method.
RESULTS: One week after injection of haloperidol decanoate, the mean D2 receptor occupancy was 73% (range = 60%-82%), and the mean plasma concentration of haloperidol was 4.6 nmol/liter (range = 2.9-9.7). After 4 weeks, the mean D2 receptor occupancy had decreased to 52% (range = 20%-74%), and the mean haloperidol concentration to 2.3 nmol/liter (range = 1.0-4.4).
CONCLUSIONS: The D2 receptor occupancy 1 week after injection was high and comparable to that previously found in patients responding to acute treatment with classic neuroleptics. Prevention of relapse was maintained despite low D2 receptor occupancy during the latter part of the treatment interval. These observations indicate that continuously high D2 receptor occupancy may not be necessary to prevent schizophrenic relapses. The results emphasize the need for systematic clinical evaluation of intermittent low-dose treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840348     DOI: 10.1176/ajp.152.2.173

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  22 in total

1.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

3.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 4.  Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.

Authors:  Mahesh N Samtani; Srihari Gopal; Cristiana Gassmann-Mayer; Larry Alphs; Joseph M Palumbo
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

5.  The recognition and optimal management of early psychosis: an evidence-based reform.

Authors:  Patrick D McGorry
Journal:  World Psychiatry       Date:  2002-06       Impact factor: 49.548

Review 6.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

7.  D2-dopamine-receptor occupancy during treatment with haloperidol decanoate.

Authors:  J Scherer; K Tatsch; M Albus; J Schwarz; T Mager; W H Oertel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 8.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 9.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

10.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.